Comparing Adicet Bio (NASDAQ:ACET) & Immunovant (NASDAQ:IMVT)

Adicet Bio (NASDAQ:ACET) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk and Volatility

Adicet Bio has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.

Institutional & Insider Ownership

83.9% of Adicet Bio shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 7.8% of Adicet Bio shares are held by company insiders. Comparatively, 1.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Adicet Bio and Immunovant, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	1	1	2	2	2.83
Immunovant	1	4	6	1	2.58

Adicet Bio currently has a consensus target price of $5.67, indicating a potential upside of 472.39%. Immunovant has a consensus target price of $28.78, indicating a potential upside of 64.35%. Given Adicet Bio’s stronger consensus rating and higher possible upside, equities analysts plainly believe Adicet Bio is more favorable than Immunovant.

Profitability

This table compares Adicet Bio and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-68.48%	-57.84%
Immunovant	N/A	-80.99%	-72.23%

Valuation and Earnings

This table compares Adicet Bio and Immunovant”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	$24.99 million	3.30	-$117.12 million	($1.31)	-0.76
Immunovant	N/A	N/A	-$413.84 million	($2.85)	-6.14

Adicet Bio has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Adicet Bio beats Immunovant on 12 of the 13 factors compared between the two stocks.

About Adicet Bio

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.